Abbott’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of adult patients with moderate to severe ulcerative colitis
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
List view / Grid view
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
6 September 2012 | By Abbott
Abbott has signed an agreement to collaborate with Astellas Pharma Global Development...
30 August 2012 | By Abbott
Approval extends HUMIRA indication to include moderately active Crohn's Disease...
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
13 August 2012 | By Abbott
40 students living with CF each to receive a $2,500 CFCareForward Scholarship...
7 August 2012 | By Abbott
The U.S. FDA has approved the Omnilink Elite® Vascular Balloon-Expandable Stent System...
30 July 2012 | By Abbott
The European Commission has approved HUMIRA®...
16 July 2012 | By Abbott
The Abbott Fund announces $1 million partnership...
Abbott will feature new solutions to improve data management and automation at this year’s American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today’s laboratories will be the focal point of the Abbott exhibit.
As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, today Abbott announced OneLab, a new, Web-based, integrated laboratory informatics solution.
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformité Européenne) for the Abbott ARCHITECT HbA1c…
6 July 2012 | By Abbott
Groundbreaking partnership that aims to speed the discovery of essential new treatments...
3 July 2012 | By Abbott
Abbott has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs)...